Mon panier

Biotinylated Human BTLA (31-150) (M105V, G138S, V148M) Protein, His,Avitag™ (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
BTA-H82E5-25ug
$360.00
BTA-H82E5-200ug
$1420.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    BTLA, CD272

  • Source

    Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), His,Avitag (BTA-H82E5) is expressed from human 293 cells (HEK293). It contains AA Lys 31 - Ser 150 (Accession # AAP44003.1 (M105V, G138S, V148M)).

    Predicted N-terminus: Lys 31

    Request for sequence
  • Molecular Characterization

    BTLA Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 17.3 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    BTLA SDS-PAGE

    Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • SEC-MALS

    BTLA SEC-MALS

    The purity of Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), His,Avitag (Cat. No. BTA-H82E5) is more than 85% and the molecular weight of this protein is around 28-36 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     BTLA ELISA

    Immobilized Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), His,Avitag (Cat. No. BTA-H82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human HVEM, Mouse IgG2a Fc Tag, low endotoxin with a linear range of 1-20 ng/mL (QC tested).

    Protocol
  •  BTLA ELISA

    Immobilized Biotinylated Human BTLA (31-150) (M105V, G138S, V148M), His,Avitag (Cat. No. BTA-H82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human HVEM, Fc Tag (Cat. No. HVM-H5258) with a linear range of 0.2-10 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

FAQ

  • Product

    Why are different expression ranges (31–134 and 31–150) used for human BTLA proteins?

    The different lengths of human BTLA proteins correspond to different isoforms. The aa31–134 sequence represents isoform 2, while aa31–150 corresponds to isoform 1. ACRO provides BTLA proteins of varying lengths to meet diverse customer requirements.

Introduction de fond

B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B- and T-lymphocyte attenuator

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    6 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • FAQ
  • Contexte